A detection kit for porcine infectious pleuropneumonia antibodies and its application

By combining fusion proteins and specific monoclonal antibodies, a highly sensitive, broad-spectrum, and low-cost method for detecting porcine infectious pleuropneumonia antibodies was established, solving the problems of incomplete detection and high cost in existing technologies and achieving more efficient diagnostic results.

CN123106926APending Publication Date: 2026-11-17浙江洪晟生物科技股份有限公司 +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611534239.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-30
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing serological diagnostic methods for porcine infectious pleuropneumonia suffer from incomplete detection, high cost, and poor stability. In particular, ELISA kits based on a single antigen are difficult to cover the antibody detection needs of different serotypes.

Method used

Develop a fusion protein comprising ApxⅠA, ApxⅡA, and OmpD proteins, link them via a flexible peptide linker, prepare specific monoclonal antibodies, establish indirect ELISA and blocking ELISA detection methods, and improve the sensitivity and broad spectrum of detection.

Benefits of technology

It significantly improves detection sensitivity, has a wider coverage, reduces production costs, and possesses good specificity and stability, making it suitable for different testing scenarios and meeting clinical needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106926A_ABST
    Figure CN123106926A_ABST
Patent Text Reader

Abstract

This invention discloses a detection kit for porcine infectious pleuropneumonia (PPH) antibodies and its applications. The kit includes a fusion protein, the amino acid sequence of which is shown in SEQ ID NO.4. This invention also discloses a monoclonal antibody that specifically binds to the fusion protein. By using the fusion protein as a coating antigen, the kit can simultaneously detect multiple antibodies against ApxIA, ApxIIA, and OmpD, with a detection sensitivity of 1:3200. Systematic validation showed no cross-reactivity with positive sera from common pathogens such as PRRSV and CSFV, with intra- and inter-assay coefficients of variation both less than 10%. This invention also provides a blocking ELISA method as a supplement, offering higher specificity. The kit of this invention has the advantages of high sensitivity, strong specificity, good reproducibility, and low cost, and is suitable for serological diagnosis, epidemiological surveys, and evaluation of vaccine immunization efficacy in porcine infectious pleuropneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to a detection kit for porcine infectious pleuropneumonia antibodies and its application. Background Technology

[0002] Porcine contagious pleuropneumonia (PCP) is a highly contagious respiratory disease caused by *Actinobacillus pleuropneumoniae* (APP), characterized by acute hemorrhagic fibrinous pneumonia and chronic fibrinous necrotizing pleuritis. Distributed in major pig-producing countries worldwide, it has become widespread in my country since its first report in 1987, becoming one of the major bacterial diseases severely restricting the healthy development of the pig industry. Nineteen serotypes of APP have been identified, with poor cross-protection between different serotypes, posing significant challenges to vaccine control and serological diagnosis. The mortality rate in acute cases can reach over 80%, while chronic cases lead to growth retardation and reduced feed efficiency, causing substantial economic losses to the pig industry.

[0003] APP has numerous virulence factors, among which repetitive sequence toxins (RTX toxins, namely ApxⅠ, ApxⅡ, ApxⅢ, and ApxⅣ) and outer membrane proteins (such as OmpD) are the main immunoprotective antigens and good targets for serological diagnosis. Apx toxins are the main hemolysins of APP, exhibiting immunogenicity and species specificity. Studies have shown that the N-terminal expressed polypeptide of ApxⅠ protein can induce the production of toxin-neutralizing antibodies, achieving a protection rate of 80%-100% against heterologous serotypes. OmpD is a highly conserved outer membrane protein. Homology analysis showed that all 19 serotypes of APP contain the ompD gene, with an amino acid sequence similarity of over 98%. Immunizing mice with OmpD can provide 70%-80% protection against serotypes 1 and 7 of the prevalent strains (ZENG Yan, OU Xianglong, YAN Xiaoyang, LIU Can, LIAO Yonghong. Prokaryotic Expression and Immunogenicity Analysis of OmpD and LppB of Actinobacillus pleuropneumoniae[J]. Acta Veterinaria et Zootechnica Sinica, 2025, 56(1): 343-352.).

[0004] Currently, serological diagnostic methods for porcine infectious pleuropneumonia mainly include complement fixation test, indirect hemagglutination test, and enzyme-linked immunosorbent assay (ELISA). Among them, ELISA has become the most commonly used diagnostic method due to its advantages such as high sensitivity, strong specificity, simple operation, and suitability for large-scale detection. Existing technologies have reported ELISA detection methods based on single Actinobacillus pleuropneumoniae toxin or OmpD. Among them, ELISA kits based on Actinobacillus pleuropneumoniae IV have been widely used in clinical detection because they can distinguish between naturally infected and vaccinated pigs (Li Jianming, Hou Jinhui, Xu Guangxin, et al. Construction of an efficient ELISA detection method to distinguish between naturally infected and vaccinated pigs with Actinobacillus pleuropneumoniae [J]. Journal of Henan Agricultural University, 2025, 59(06):1028-1036.).

[0005] However, existing single-antigen-based detection methods have significant drawbacks: First, while ApxIV-based ELISA can distinguish between naturally infected and vaccine-immunized pigs, ApxIV expression levels are low, purification is difficult, and its ability to assess antibody levels after vaccine immunization is limited. Second, ELISA based on a single Apx toxin may miss pigs infected with certain strains due to serotype differences. Different APP serotypes secrete different toxin profiles, and a single toxin antigen cannot cover the antibody detection needs of all serotypes. Third, while ELISA based on a single OmpD protein exhibits good conservation, it is difficult to achieve comprehensive capture of antibodies against different virulence factors.

[0006] Combining multiple antigens can improve the breadth and accuracy of detection, but separately expressing and purifying multiple proteins significantly increases production costs and process complexity, and quality variations between different batches of proteins may affect the stability of the kit. Therefore, developing a detection kit that can simultaneously detect multiple APP antibodies, has low production costs, and good stability has significant clinical application value and market prospects. Summary of the Invention

[0007] The purpose of this invention is to overcome the shortcomings of the prior art and provide a detection kit and its core raw materials that can simultaneously detect multiple porcine infectious pleuropneumonia antibodies, have low production cost, good stability, high sensitivity, and strong specificity.

[0008] To achieve the above objectives, the present invention provides the following technical solution: 1. Fusion proteins and their preparation The present invention first provides a fusion protein comprising ApxⅠA protein, ApxⅡA protein and OmpD protein of Actinobacillus pleuropneumoniae, and the three proteins are connected by a flexible peptide linker.

[0009] Preferably, the ApxⅠA protein is extracted from its N-terminal hydrophilic region (SEQ ID NO. 1), which exhibits good immunogenicity and can induce the production of toxin-neutralizing antibodies. The ApxⅡA protein is extracted from its central hydrophilic region (SEQ ID NO. 2), which, according to B-cell epitope prediction, contains multiple high antigenicity index fragments. The OmpD protein is extracted from its extracellular loop enriched region (SEQ ID NO. 3), retaining the major antigenic epitopes.

[0010] More preferably, the amino acid sequence of the flexible peptide linker is (GGGGS)3. Preliminary experiments have verified that this linker can ensure that each protein domain folds independently without interfering with each other.

[0011] Most preferably, the amino acid sequence of the fusion protein is shown in SEQ ID NO.4, and its structure is: ApxⅠA -(GGGGS)3 - ApxⅡA - (GGGGS)3 - OmpD- 6×His tag.

[0012] The present invention also provides a nucleic acid molecule encoding the above-mentioned fusion protein, the nucleotide sequence of which is optimized by E. coli preferred codons as shown in SEQ ID NO.5.

[0013] 2. Monoclonal antibodies and their preparation This invention also provides a monoclonal antibody that specifically binds to the aforementioned fusion protein. The monoclonal antibody is prepared using hybridoma technology with the fusion protein as an immunogen. Three stable antibody-secreting hybridoma cell lines were obtained through screening and named 3A-F6, 3A-G8, and 3A-H11, respectively. Among them, monoclonal antibody 3A-F6 was identified as the IgG1 / κ subtype with an affinity constant as high as 5.6 × 10⁻⁶. 9 L / mol. Western blot analysis showed that 3A-F6 specifically recognizes ApxⅠA, 3A-G8 specifically recognizes ApxⅡA, and 3A-H11 specifically recognizes OmpD.

[0014] Preferably, the heavy chain variable region nucleotide sequence of the monoclonal antibody 3A-F6 is shown in SEQ ID NO.6, and the light chain variable region nucleotide sequence is shown in SEQ ID NO.7.

[0015] 3. Detection kits and their applications: Based on the above-mentioned fusion protein and monoclonal antibody, this invention provides two types of detection kits for porcine infectious pleuropneumonia antibodies: 3.1 Indirect ELISA Detection Kit: The kit includes an enzyme-labeled plate coated with the above-mentioned fusion protein. After system optimization, the optimal reaction conditions were determined to be: antigen coating concentration 2 μg / mL, serum dilution factor 1:100, and HRP-labeled rabbit anti-pig IgG working concentration 1:10000. The positive cutoff value determined based on 120 negative serum samples was OD450nm ≥ 0.15.

[0016] 3.2 Blocking ELISA Detection Kit: The kit comprises a solid-phase carrier coated with the above-described fusion protein and HRP-labeled monoclonal antibody (preferably 3A-F6). Optimized reaction conditions are: antigen coating concentration 2 μg / mL, enzyme-labeled monoclonal antibody working concentration 1:4000, and competitive reaction time 30 minutes. The positive cutoff value, determined based on 120 negative serum samples, is a blocking rate ≥ 20%.

[0017] Compared with the prior art, the present invention has the following beneficial effects: (1) Significant synergistic enhancement effect and greatly improved detection sensitivity: This invention uses the fusion expression of three advantageous antigens, ApxⅠA, ApxⅡA, and OmpD, as coating antigens. Sensitivity verification results (Example 4.1) show that the highest detection dilution of the kit of this invention is 1:3200, while the highest detection dilutions of the single antigen coating kits are: ApxⅠA 1:800, ApxⅡA 1:800, and OmpD 1:400. The detection sensitivity of the kit of this invention is 4 times higher than that of the single antigen kit. Statistical analysis shows that at a dilution of 1:1600, the OD450nm value of the kit of this invention (0.278±0.022) is higher than that of ApxⅠA (0.158±0.014, P<0.01), ApxⅡA (0.172±0.016, P<0.01), and OmpD (0.098±0.009, P<0.001), confirming the synergistic enhancement effect of the fusion protein. This advantage can effectively avoid missed detections due to differences in individual immune responses, thus improving the accuracy of clinical testing.

[0018] (2) Broad-spectrum detection with wider coverage: The fusion protein of this invention contains three antigens, enabling simultaneous detection of multiple antibodies against ApxIA, ApxIIA, and OmpD, covering the main immunogenic antigens of APP. Clinical concordance verification with imported commercial kits (based on a single ApxIV antigen) showed a total concordance rate of 94.5% and a Kappa value of 0.89, indicating high consistency. Particularly noteworthy is that further analysis of 11 inconsistent samples revealed that of the 6 positive samples detected by the kit of this invention (negative with the imported kit), 4 were ApxIA positive, 1 was ApxIIA positive, and 1 was OmpD positive. This indicates that the kit of this invention can detect some specific antibodies that the imported kit cannot detect, providing broader detection coverage.

[0019] (3) Significantly reduced production costs: By adopting a fusion protein strategy, only one protein needs to be expressed and purified to replace the separate expression of three proteins, simplifying the process. Through codon optimization and expression condition optimization, the fusion protein is highly expressed in the form of inclusion bodies, with a yield of 510 mg / L fermentation broth. After purification, the purity is greater than 90%, which fully meets the requirements of industrial production and significantly reduces production costs.

[0020] (4) Good specificity and no cross-reaction with common pathogens: Specificity verification showed (Example 4.2) that the kit of the present invention did not cross-react with positive sera of common pathogens such as porcine reproductive and respiratory syndrome virus (PRRSV), classical swine fever virus (CSFV), pseudorabies virus (PRV), porcine circovirus type 2 (PCV2), Streptococcus suis (SS), and Haemophilus parasuis (HPS), indicating that the kit of the present invention has excellent specificity.

[0021] (5) Good repeatability and stability: Repeatability verification (Example 4.3) showed that the intra-batch coefficient of variation was 3.2%-7.3% and the inter-batch coefficient of variation was 5.6%-9.4%, both less than 10%, meeting the quality requirements of the Chinese Veterinary Pharmacopoeia for ELISA kits. Stability verification (Example 4.4) showed that the kit's performance still met the requirements after being stored at 4°C for 12 months. According to the Arrhenius formula, the shelf life can be estimated to be 12-18 months, meeting the requirements for commercial production and clinical use.

[0022] (6) Two detection modes are provided to meet different application scenarios: In addition to indirect ELISA, this invention also establishes a blocking ELISA method based on the prepared monoclonal antibody (Example 5). This method has higher specificity and is suitable for detection scenarios that require higher specificity (such as distinguishing between vaccine immunization and natural infection, and retesting of high background samples). The two methods complement each other and can meet different detection needs.

[0023] (7) Self-sufficient and controllable core raw materials: This invention provides the amino acid sequence (SEQ ID NO.4) and encoding gene (SEQ ID NO.5) of the fusion protein, as well as the variable region sequence (SEQ ID NO.6 and SEQ ID NO.7) of the specific monoclonal antibody 3A-F6. The sequences of these core raw materials are well-defined, can be prepared independently, and have good prospects for industrialization.

[0024] In summary, the porcine infectious pleuropneumonia antibody detection kit provided by this invention has significant advantages in terms of sensitivity, specificity, repeatability, stability, broad spectrum, and production cost. It provides a new technical means for the serological diagnosis, epidemiological investigation, and evaluation of vaccine immunization efficacy of porcine infectious pleuropneumonia, and has good clinical application value and market prospects. Attached Figure Description

[0025] Figure 1 SDS-PAGE results of fusion protein expression and purification.

[0026] Figure 2 SDS-PAGE analysis of the purified fusion protein product. 1 represents the purified fusion protein.

[0027] Figure 3 Western blot identification results of the fusion protein. M: protein molecular weight standard; 1: reaction with APP standard positive serum; 2: reaction with porcine negative serum; 3: reaction with anti-ApxⅠA rabbit polyclonal antibody; 4: reaction with anti-ApxⅡA rabbit polyclonal antibody; 5: reaction with anti-OmpD rabbit polyclonal antibody.

[0028] Figure 4 SDS-PAGE results of purified monoclonal antibody 3A-F6. M: protein molecular weight standard; 1: under reducing conditions, two bands are shown, one for the heavy chain (approximately 50 kDa) and one for the light chain (approximately 25 kDa).

[0029] Figure 5 Western blot results for specific identification of monoclonal antibodies. A: 3A-F6 monoclonal antibody; B: 3A-G8 monoclonal antibody; C: 3A-H11 monoclonal antibody. M: Protein molecular weight standard; 1: ApxIA single protein; 2: ApxIIA single protein; 3: OmpD single protein; 4: Fusion protein. The results show that 3A-F6 reacts only with ApxIA and the fusion protein, 3A-G8 reacts only with ApxIIA and the fusion protein, and 3A-H11 reacts only with OmpD and the fusion protein. Detailed Implementation

[0030] Example 1: Design, expression and purification of fusion proteins 1.1 Construction of fusion genes 1.1.1 Basis for selecting the target protein truncated fragment: In this study, the immunodominant regions of three antigens, ApxⅠA, ApxⅡA, and OmpD, were selected for fusion expression. The specific truncation scheme was based on the following scientific considerations: ApxIA protein extraction protocol: Amino acids 1-398 were selected (SEQ ID NO.1). This fragment corresponds to the N-terminal hydrophilic region of the ApxIA protein, containing major T-cell and B-cell epitopes. Studies have shown that the N-terminal region of ApxIA (positions 1-398) has good immunogenicity and can induce the production of toxin-neutralizing antibodies.

[0031] Apx IIA protein extraction protocol: Amino acids 287-696 (SEQ ID NO.2) were selected, totaling 410 amino acids. This fragment was selected based on the following analysis: B-cell epitope prediction showed that this region contains multiple fragments with high antigenicity.

[0032] OmpD protein extraction protocol: Amino acids 50-454 (SEQ ID NO.3) were selected, totaling 405 amino acids. This region contains multiple extracellular loops of the OmpD protein, which are the main concentration areas of antigenic epitopes; analysis revealed multiple potential B-cell linear epitopes within this region, exhibiting good antigenicity.

[0033] 1.1.2 Design and Optimization of Flexible Peptide Linkers To ensure that each protein domain can fold independently and without interference after fusion, flexible peptide linkers were introduced between ApxⅠA and ApxⅡA, and between ApxⅡA and OmpD. Preliminary experiments compared the effects of three linker lengths: linker A: (GGGGS)1 (5 amino acids); linker B: (GGGGS)3 (15 amino acids); and linker C: (GGGGS)5 (25 amino acids).

[0034] Expression vectors containing fusion genes with different adapters were constructed, transformed into BL21(DE3), and induced to express. The reactivity of the fusion proteins with APP-positive serum was detected by Western blot. The results showed that the fusion protein corresponding to adapter B ((GGGGS)3) had the highest expression level (accounting for 32% of the total bacterial protein) and the strongest immunoreactivity (highest gray value in the Western blot band). Adapter A may have partially masked antigenic epitopes due to steric hindrance, while adapter C, being too long, may increase sensitivity to protease degradation. Therefore, (GGGGS)3 was selected as the optimal adapter sequence in this study.

[0035] 1.1.3 Synthesis and Codon Optimization of Fusion Genes The three truncated fragments were tandemly linked using the (GGGGS)3 linker to obtain the amino acid sequence of the fusion protein, as shown in SEQ ID NO.4. Its structure is: ApxⅠA(1-398) - (GGGGS)3 - ApxⅡA(287-696) - (GGGGS)3 - OmpD(50-454)-6×His tag. To improve expression efficiency in prokaryotic systems, the nucleotide sequence encoding this fusion protein was optimized using E. coli-preferred codons. The optimized nucleotide sequence of the fusion gene is shown in SEQ ID NO.5.

[0036] The synthesized fusion gene was cloned into the expression vector pET-28a(+) between the BamHI and XhoI sites to construct the recombinant plasmid pET-28a-3A, which was then transformed into *E. coli* DH5α competent cells. After identification by bacterial culture PCR and BamHI / XhoI double digestion, the plasmid was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing verification. The sequencing results were completely consistent with SEQ ID NO. 5, indicating that the recombinant plasmid was successfully constructed.

[0037] 1.2 Optimization of expression conditions for fusion proteins 1.2.1 The correctly sequenced recombinant plasmid pET-28a-3A was transformed into the expression host bacterium E. coli BL21(DE3). To obtain optimal expression conditions, the induction temperature, IPTG concentration, and induction time were systematically optimized: Temperature optimization: Four induction temperatures were set at 16℃, 25℃, 30℃, and 37℃, with other conditions remaining the same (IPTG 0.5mM, induction for 6h). SDS-PAGE analysis showed that the target protein expression level was highest at 37℃, while the total expression level was significantly reduced at 16℃. Therefore, 37℃ was selected as the optimal induction temperature.

[0038] IPTG concentration optimization: Four concentration gradients of 0.1, 0.2, 0.5, and 1.0 mM were set, and induction was performed at 37℃ for 6 h. The results showed that the target protein expression level was highest when induced by 0.5 mM IPTG, and further increasing the concentration to 1.0 mM did not significantly increase the expression level. Therefore, 0.5 mM was selected as the optimal IPTG concentration.

[0039] Induction time optimization: Induction was performed for 2, 4, 6, 8, and 10 hours, with periodic sampling and analysis. Results showed that the expression level of the target protein reached a plateau at 6 hours of induction; further extending the induction time did not significantly increase expression levels and may even increase the risk of protein degradation. Therefore, 6 hours of induction was selected as the optimal time.

[0040] 1.2.2 Based on the above optimization results, the optimal expression conditions were determined to be: 37℃, IPTG 0.5mM, and induction for 6 hours. The specific procedures are as follows: Single colonies were picked and inoculated into 5 mL of LB medium containing kanamycin (50 μg / mL), and cultured overnight at 37°C with shaking at 220 rpm. The next day, they were transferred to fresh LB medium at a 1:100 ratio and cultured at 37°C with shaking at 220 rpm until OD reached. 600 The concentration was approximately 0.6-0.8. IPTG was added to a final concentration of 0.5 mM, and expression was induced at 37°C for 6 hours. A non-induced control was also included. After induction, the bacterial cells were collected by centrifugation at 4°C and 8000 rpm for 10 minutes, and washed twice with PBS.

[0041] Add an appropriate amount of bacterial cells to SDS-PAGE loading buffer, incubate in boiling water for 10 minutes, and then perform 12% SDS-PAGE electrophoresis. The results showed that, compared with the uninduced control, a clear target protein band appeared at approximately 137 kDa after induction. Figure 1 This is basically consistent with the expected theoretical molecular weight of the fusion protein.

[0042] 1.3 Purification of the fusion protein After induction, bacterial cells were collected, and 10 mL of lysis buffer (50 mM NaH₂PO₄, 300 mM NaCl, 10 mM imidazole, pH 8.0) was added per gram of wet cells. The cells were resuspended and then sonicated in an ice bath (300 W, 3 seconds on, 5 seconds off, for a total of 30 minutes). The lysate was centrifuged at 12000 rpm for 30 minutes at 4°C, and the supernatant and precipitate were collected separately for SDS-PAGE analysis. The results showed ( Figure 1 The target protein mainly exists in the precipitate in the form of inclusion bodies.

[0043] Inclusion bodies were washed with PBS and dissolved overnight at 2–8°C in binding buffer containing 8M urea (50mM NaH₂PO₄, 300mM NaCl, 20mM imidazole, pH 8.0). After centrifugation (10000 rpm for 30 min), the supernatant was filtered through a 0.45 μm filter and purified using a HisTrap™ FF (5 mL) nickel ion affinity chromatography column. The purification procedure is as follows: Equilibration: Equilibrate the column with 5 column volumes of binding buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) at a flow rate of 2 mL / min.

[0044] Sample loading: Load the sample at a flow rate of 1 mL / min and collect the flow-through liquid.

[0045] Washing: Wash with binding buffer until the UV280 baseline is stable, approximately 5-8 column volumes.

[0046] Elution: Perform linear gradient elution (0-100%, 10 column volumes) with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) and collect the elution peaks.

[0047] Regeneration: Wash the column with 1M NaOH, then equilibrate with ultrapure water, and store with 20% ethanol.

[0048] The elution peak sample was collected and analyzed by SDS-PAGE. The results showed a single band at approximately 137 kDa, and the purity was greater than 90% according to software analysis. Figure 2 The protein concentration was determined using the BCA method, with three repeated measurements and the average value taken. The concentration of the purified fusion protein was found to be 1.25 ± 0.08 mg / mL. Based on the fermentation broth volume, the purified protein yield was approximately 510 mg / L. The purified protein was aliquoted and stored at -80℃ for later use.

[0049] 1.4 Immunoreactivity identification of fusion proteins 1.4.1 Western blot identification The purified fusion protein was identified by Western blot. The specific steps are as follows: (1) After electrophoresis of the purified protein with 12% SDS-PAGE, it was transferred to a PVDF membrane (0.45 μm) using a semi-dry transfer instrument. The transfer conditions were 15V for 30 minutes. (2) The membrane was placed in TBST containing 5% skim milk powder and blocked at room temperature for 2 hours. (3) It was incubated with the following primary antibodies: APP standard positive serum (1:100 dilution, prepared in our laboratory), porcine negative serum (1:100 dilution, prepared in our laboratory), and anti-ApxⅠA rabbit polyclonal antibody (1:100 dilution). (3) Anti-Apx IIA rabbit polyclonal antibody (1:1000 dilution, self-made in this laboratory), anti-OmpD rabbit polyclonal antibody (1:1000 dilution, self-made in this laboratory), incubated overnight at 4℃; (4) washed 5 times with TBST, 5 minutes each time; (5) incubated with the corresponding HRP-labeled secondary antibody (rabbit anti-pig IgG or goat anti-rabbit IgG, 1:5000 dilution) at room temperature for 1 hour; (6) washed 5 times with TBST, reacted with ECL chromogenic solution for 1 minute, and detected by chemiluminescence imaging system.

[0050] The results show that ( Figure 3 The fusion protein showed a strong positive reaction with APP-positive serum but no reaction with APP-negative serum. The fusion protein also showed positive reactions with anti-ApxIA, anti-ApxIIA, and anti-OmpD specific antibodies, with the bands appearing in the same location (approximately 137 kDa). This indicates that the fusion protein completely retains the antigenic epitopes of the three components: ApxIA, ApxIIA, and OmpD, and that the introduction of the flexible peptide linker did not affect the immunoreactivity of any of the domains.

[0051] 1.4.2 Indirect ELISA Validation To assess the immunoreactivity of the fusion protein, the purified fusion protein was coated onto ELISA plates at a concentration of 2 μg / mL and reacted with serially diluted APP-positive serum (1:100 to 1:12800). HRP-labeled rabbit anti-pig IgG (1:10000) was used as the secondary antibody. After TMB color development, OD450nm was measured. Simultaneously, single-protein coated plates of ApxIA, ApxIIA, and OmpD were used as controls.

[0052] The results (Table 1) showed that the titer of the fusion protein-coated plate reacting with positive serum (1:6400, with OD≥0.3 as the criterion) was higher than that of any single protein-coated plate. This indicates that the three antigenic epitopes were completely preserved after fusion, and their binding ability to antibodies may have been enhanced due to the synergistic effect of spatial conformation.

[0053] Table 1-1 Comparison of immunoreactivity between fusion proteins and single antigens

[0054] Example 2: Preparation and Identification of Monoclonal Antibodies Against Fusion Proteins 2.1 Animal Immunization and Serum Titer Monitoring The purified fusion protein from Example 1 was used as an immunogen to immunize 6-8 week old female BALB / c mice. The specific procedures were as follows: First immunization (day 0): 50 μg of fusion protein was thoroughly emulsified with an equal volume of Freund's complete adjuvant and injected subcutaneously at five points on the back, 100 μL per point; Second immunization (day 14): 25 μg of fusion protein was emulsified with an equal volume of Freund's incomplete adjuvant and injected intraperitoneally; Third immunization (day 28): Same as the second immunization; Blood collection and monitoring (day 35): Blood was collected from the tail vein, serum was separated, and antibody titer was determined using indirect ELISA (fusion protein coating concentration 2 μg / mL, serum serially diluted starting at 1:1000); Booster immunization (day 38): Mice with the highest titer (serum titer >1:10) were selected. 5 ), 25 μg of fusion protein (without adjuvant, dissolved in 200 μL sterile PBS) was injected via tail vein; cell fusion (day 41): 3 days after booster immunization, spleen was aseptically harvested for cell fusion.

[0055] The serum antibody titer monitoring results (Table 2-1) showed that the serum antibody titers of the three immunized mice reached 1:10 after three immunizations. 5 Of the above, mouse number 2 had the highest titer (1:512,000) and was selected as the fusion mouse.

[0056] Table 2-1 Results of serum antibody titer monitoring in immunized mice

[0057] 2.2 Preparation of myeloma cells Two weeks prior to fusion, mouse myeloma cells Sp2 / 0 were resuscitated and cultured. They were cultured in DMEM complete medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator. Twenty-four hours before fusion, the cells were passaged to the logarithmic growth phase (cell density approximately 5 × 10⁶ cells / year). 5 / mL (viability >95%). On the day of fusion, cells were collected, washed twice with serum-free DMEM, and resuspended for later use.

[0058] 2.3 Preparation of spleen cells Three days after booster immunization, mice (number 2) were sacrificed by exophthalmos, and serum was collected as a positive control. The spleens were aseptically removed by immersion in 75% alcohol for 5 minutes and placed in a culture dish containing 10 mL of serum-free DMEM. The spleens were ground using a sterile syringe core, filtered through a 200-mesh cell sieve, and the cell suspension was collected. The cells were washed twice with serum-free DMEM (1000 rpm, 10 minutes) and counted. Approximately 1.2 × 10⁻⁶ nucleated cells were obtained from each mouse spleen. 8 Vitality > 95%.

[0059] 2.4 Cell Fusion Splenocytes were mixed with Sp2 / 0 cells at a ratio of 5:1 (1 × 102 splenocytes). 8 Sp2 / 0 cells 2×10 7 Wash once with serum-free DMEM, discard the supernatant, and gently tap to disperse the cell pellet. In a 37°C water bath, slowly add 1 mL of 50% PEG 4000 (preheated to 37°C) over 1 minute while gently stirring. Continue stirring for 1 minute, then slowly add 30 mL of serum-free DMEM over 2 minutes to terminate the fusion (1 mL in the first minute, 4 mL in the second minute, and 25 mL in the third-to-fifth minutes). Centrifuge the fused cells at 1000 rpm for 10 minutes, discard the supernatant, and resuspend in complete culture medium containing HAT (hypoxanthine, aminopterin, thymidine), adjusting the cell density to 2 × 10⁶ cells / mL. 6 200 μL (approximately 4 × 10⁶ cells / mL) was seeded into 10 96-well cell culture plates, with each well containing 200 μL (approximately 4 × 10⁶ cells / mL). 5 Spleen cells / well). Incubate at 37°C in a 5% CO2 incubator.

[0060] 2.5 Screening and Cloning of Hybridoma Cells 2.5.1 Post-fusion culture and observation On day 3 post-fusion, add 50 μL of complete medium containing HAT to each well. On day 7 post-fusion, replace with complete medium containing HT (hypoxanthine, thymidine). Observe cell growth daily under an inverted microscope. On days 10-14 post-fusion, when hybridoma cell clones have grown to 1 / 10-1 / 5 of the well bottom area, collect the culture supernatant for antibody detection.

[0061] 2.5.2 Screening of positive clones (indirect ELISA) The fusion protein purified in Example 1 (2 μg / mL) was coated onto an ELISA plate and incubated overnight at 4°C. The plate was washed three times with PBST, and blocking buffer (PBST containing 1% BSA) was added, followed by blocking at 37°C for 2 hours. 50 μL of hybridoma culture supernatant was added to each well, along with a positive control (immunized mouse serum diluted 1:5000), a negative control (Sp2 / O culture supernatant), and a blank control (culture medium). The plate was incubated at 37°C for 1 hour. After washing, HRP-labeled goat anti-mouse IgG (1:5000 diluted) was added, and the plate was incubated at 37°C for 30 minutes. TMB was developed after washing, and the reaction was stopped with 2M H2SO4. OD was measured at 450 nm.

[0062] Screening results: A total of 10 96-well plates (960 wells) were screened. The fusion rate was calculated as follows: 887 wells showed hybridoma cell growth, fusion rate = 887 / 960 × 100% = 92.4%. 156 wells were initially positive (OD450nm ≥ 1.0), positive rate = 156 / 887 × 100% = 17.6%. The 24 positive wells with the highest OD450nm values ​​were selected for the next step of cloning.

[0063] 2.5.3 Cloning by Limiting Dilution Cells from the initial screening positive wells were dispersed, counted, and diluted to 10 cells / mL. 100 μL of this solution was seeded into each well of a 96-well plate (i.e., 1 cell / well). The plates were incubated at 37°C in a 5% CO2 incubator. On days 7-10, wells showing single-clone growth (wells with only one cell cluster) were observed and labeled under a microscope. The supernatant from the single-clone wells was collected for re-ELISA detection. The cloning process was repeated twice in selected positive wells (a total of 3 subclonings).

[0064] After three subcloning processes, three hybridoma cell lines that stably secrete monoclonal antibodies against the fusion protein were obtained and named 3A-F6, 3A-G8, and 3A-H11, respectively. The cell lines were then expanded and cryopreserved in liquid nitrogen (cryopreservation solution: 90% FBS + 10% DMSO).

[0065] 2.6 Preparation and purification of monoclonal antibodies 2.6.1 Ascites preparation Ten-week-old female BALB / c mice were sensitized by intraperitoneal injection of 0.5 mL of liquid paraffin. Seven days later, each mouse was injected intraperitoneally with 5 × 10⁶ hybridoma cells. 5 Each mouse was resuspended in serum-free DMEM. 7-14 days post-inoculation, the abdominal distension of the mice was observed. Ascites fluid was collected using a 16-gauge needle; generally, 3-5 mL of ascites fluid could be collected from each mouse. The ascites fluid was centrifuged at 8000 rpm for 10 minutes at 4°C, and the supernatant was collected and stored at -80°C for later use.

[0066] 2.6.2 Antibody Purification Monoclonal antibodies were purified using a Protein G affinity chromatography column (HiTrap Protein G HP, 1 mL). The specific steps were as follows: The column was equilibrated with 5 column volumes of binding buffer (20 mM sodium phosphate buffer, pH 7.0); ascites fluid was diluted 2-fold with binding buffer and filtered through a 0.45 μm filter, then loaded at a flow rate of 1 mL / min; the column was washed with binding buffer until the UV280 baseline stabilized, approximately 10 column volumes; elution was performed with elution buffer (0.1 M glycine-HCl, pH 2.7), the elution peak was collected, and immediately neutralized to pH 7.0 with 1 / 10 volume of 1 M Tris-HCl (pH 9.0); the eluent was transferred to a dialysis bag (MWCO 10 kDa) and dialyzed overnight in PBS (pH 7.4) at 4°C; the eluent was concentrated to an appropriate volume with PEG 20000 and filtered through a 0.22 μm filter for sterilization.

[0067] SDS-PAGE analysis showed that the purified antibody exhibited two bands under reducing conditions (heavy chain approximately 50 kDa, light chain approximately 25 kDa). Figure 4 BandScan software analysis showed a purity greater than 95%.

[0068] 2.6.3 Antibody Concentration Determination The concentrations of the purified antibodies were determined using the BCA method. The concentrations of the three monoclonal antibodies were: 3A-F6 2.35 mg / mL, 3A-G8 1.98 mg / mL, and 3A-H11 2.12 mg / mL.

[0069] 2.7 Characterization of Monoclonal Antibodies 2.7.1 Antibody titer determination The titers of purified monoclonal antibodies were determined using indirect ELISA. ELISA plates were coated with fusion protein (2 μg / mL), and the purified antibodies were serially diluted from 1:1000 (to 1:1,024,000), with OD450nm measured according to standard ELISA procedures. The highest dilution with OD450nm ≥ 0.3 was taken as the antibody titer. The results (Table 2-2) showed that the titers of all three monoclonal antibodies were above 1:256,000, with 3A-F6 exhibiting the highest titer (1:512,000).

[0070] Table 2-2 Results of Monoclonal Antibody Titer Determination

[0071] 2.7.2 Antibody Subclass Identification Identification was performed using a mouse monoclonal antibody subclass identification kit. The procedure was performed according to the manufacturer's instructions: the fusion protein was coated onto an ELISA plate, and the monoclonal antibody culture supernatant (1:10 dilution) was added and incubated. Rabbit anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgA, IgM, κ chain, and λ chain antibodies were added, respectively. After incubation, HRP-labeled goat anti-rabbit IgG was added, and colorimetric assay was performed. The results (Table 2-3) showed that the heavy chains of all three monoclonal antibodies belonged to the IgG1 subclass, and the light chains belonged to the κ type.

[0072] Table 2-3 Results of Monoclonal Antibody Subclass Identification

[0073] 2.7.3 Antibody Affinity Assay The affinity constant (Ka) of monoclonal antibodies was determined using a non-competitive ELISA method. Fusion proteins were coated onto ELISA plates at concentrations of 0.5, 1.0, 2.0, and 4.0 μg / mL, respectively. Different concentrations of monoclonal antibody (serially diluted starting from 1:1000) were added, and OD450nm was measured using standard ELISA procedures. A curve was plotted with the logarithm of antibody concentration (mol / L) on the x-axis and OD450nm value on the y-axis. The antibody concentration [Ab]t at which the maximum OD value was reached (50%) was calculated. The affinity constant (where n is the factor of the antigen coating concentration) was calculated using the formula Ka = (n-1) / 2(n[Ab]t' - [Ab]t). The results (Table 2-4) showed that the affinity constants of the three monoclonal antibodies were all within 10. 9 The concentration is on the order of L / mol, classifying them as high-affinity antibodies, with 3A-F6 exhibiting the highest affinity (Ka = 5.6 × 10⁻⁶). 9 L / mol).

[0074] Table 2-4 Results of Monoclonal Antibody Affinity Constant Determination

[0075] 2.7.4 Antibody specificity identification: The specificity of monoclonal antibodies was identified using Western blot and indirect ELISA.

[0076] Western blot identification: The fusion protein, ApxⅠA single protein, ApxⅡA single protein, and OmpD single protein prepared in Example 1 (all prepared in our laboratory) were transferred to membranes after SDS-PAGE electrophoresis and incubated with three monoclonal antibodies (1 μg / mL). HRP-labeled goat anti-mouse IgG (1:5000) was used as the secondary antibody, and ECL staining was performed. The results showed that ( Figure 5 All three monoclonal antibodies reacted with the corresponding bands in the fusion protein, but their reaction patterns with the individual ApxIA, ApxIIA, and OmpD proteins differed: 3A-F6 reacted only with ApxIA, 3A-G8 only with ApxIIA, and 3A-H11 only with OmpD. This indicates that the three monoclonal antibodies recognize different components of the fusion protein: 3A-F6 is an anti-ApxIA-specific monoclonal antibody, 3A-G8 is an anti-ApxIIA-specific monoclonal antibody, and 3A-H11 is an anti-OmpD-specific monoclonal antibody.

[0077] Cross-reactivity ELISA: Positive sera from pathogens such as PRRSV, CSFV, PRV, PCV2, SS, and HPS were coated onto ELISA plates (1:100 dilution), and monoclonal antibodies (1 μg / mL) were added and incubated. HRP-labeled goat anti-mouse IgG was then used for detection. The results showed that none of the three monoclonal antibodies showed cross-reactivity with these pathogens (OD450nm <0.15 for all).

[0078] 2.8 Cloning and Sequence Analysis of Monoclonal Antibody Variable Region Genes 2.8.1 Total RNA extraction: Harvest hybridoma cells 3A-F6 (approximately 5 × 10⁶ cells) 6 Total RNA was extracted using TRIzol reagent (samples). RNA concentration and purity were determined using a UV spectrophotometer. 260 / A 280 = 1.98, concentration 350 ng / μL. Clear 28S and 18S rRNA bands were observed on 1% agarose gel electrophoresis, indicating good RNA integrity.

[0079] 2.8.2 cDNA Synthesis: Take 2 μg of total RNA and use Oligo(dT) 18 Primers and SuperScript III reverse transcriptase were used to synthesize the first strand of cDNA. Reaction conditions: 65℃ for 5 minutes, ice bath for 2 minutes, 50℃ for 60 minutes, and 70℃ for 15 minutes.

[0080] 2.8.3 PCR Amplification: Primers for the variable regions of the heavy and light chains were synthesized according to the universal primers for mouse IgG reported in the literature. PCR amplification was performed using cDNA as a template. Reaction system: 2 μL cDNA, 5 μL 10×PCR Buffer, 4 μL dNTPs (2.5 mM), 2 μL each of forward and reverse primers (10 μM), 0.5 μL Taq DNA polymerase (5 U / μL), and ddH2O to a final volume of 50 μL. Reaction conditions: 94℃ pre-denaturation for 5 min; 94℃ denaturation for 30 s, 58℃ annealing for 30 s, 72℃ extension for 45 s, for a total of 35 cycles; 72℃ extension for 10 min. PCR products were detected by 1.5% agarose gel electrophoresis. Specific bands appeared at approximately 360 bp and 330 bp for the heavy and light chains, respectively. The target bands were excised from the gel and purified using a gel extraction kit.

[0081] 2.8.4 TA Cloning and Sequencing: The purified PCR product was ligated into the pMD18-T vector and incubated overnight at 16°C. The ligation product was transformed into DH5α competent cells and plated on LB agar plates containing Amp, IPTG, and X-gal, and incubated overnight at 37°C. White single colonies were picked and identified by colony-linked PCR. Positive clones were sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing.

[0082] 2.8.5 Sequence analysis: Sequencing results were compared with NCBI Blast and analyzed online with IMGT / V-QUEST. The variable region sequence of monoclonal antibody 3A-F6 was determined as follows: heavy chain variable region nucleotide sequence (SEQ ID NO.6); light chain variable region nucleotide sequence (SEQ ID NO.7).

[0083] Example 3: Establishment and optimization of ELISA detection method 3.1 Single-factor optimization of reaction conditions: Before performing matrix titration, the key conditions of the ELISA reaction were optimized by single factors, including coating conditions, blocking conditions, reaction time and color development time.

[0084] 3.1.1 Optimization of Coating Conditions: Two conditions were compared: overnight coating at 4℃ (12-14 hours) and coating at 37℃ (2 hours). The fusion protein was coated onto an ELISA plate at 2 μg / mL, and after treatment under the above conditions, the same positive serum sample (1:100 dilution) was tested. The results showed that the positive OD450nm value of overnight coating at 4℃ was 1.158, significantly higher than that of coating at 37℃ (0.876). Therefore, overnight coating at 4℃ was chosen.

[0085] 3.1.2 Optimization of blocking solution: Four blocking solutions—1% BSA, 3% BSA, 5% skim milk powder, and 1% gelatin—were compared, and the solutions were blocked at 37℃ for 2 hours. The results showed that 1% BSA had the best blocking effect, the highest P / N value (11.8), and the lowest background value (negative OD450nm=0.078). Therefore, 1% BSA was selected as the blocking solution.

[0086] 3.1.3 Optimization of reaction time and color development time: Serum incubation time (30 min, 45 min, 60 min) and TMB color development time (5 min, 10 min, 15 min) were compared. Results showed that compared to 30 min, serum incubation for 60 min increased the positive OD450nm value by approximately 25%, but the negative OD450nm value also increased slightly. Considering ease of operation, 30 min was chosen as the serum incubation time, at which point the positive OD450nm value reached 1.036, meeting the detection requirements. The P / N value reached its peak at 10 min of color development; further extending the color development time resulted in a significant increase in the background value; therefore, 10 min of color development was selected.

[0087] 3.2 Optimization of antigen coating concentration and serum dilution factor (square matrix titration): Based on the single-factor optimization, the optimal antigen coating concentration and serum dilution factor were further determined by square matrix titration.

[0088] The purified fusion protein from Example 1 was diluted to 0.5, 1, 2, 4, and 8 μg / mL with coating buffer (0.05 M carbonate buffer, pH 9.6). 100 μL was added to each well of a 96-well microplate (Corning), with three replicates for each concentration. The plates were incubated overnight (12-14 hours) at 4°C. The next day, the coating buffer was discarded, and the plates were washed three times with 300 μL of PBST (PBS containing 0.05% Tween-20, pH 7.4), and then blotted dry. 200 μL of blocking buffer (PBST containing 1% BSA) was added to each well, and the plates were blocked at 37°C for 2 hours. The blocking buffer was then discarded, and the plates were blotted dry.

[0089] APP standard positive serum (prepared in our laboratory, with a titer >1:10 as verified by indirect ELISA) was used. 5 Porcine negative serum (prepared in our laboratory) and sample diluent (PBST containing 0.5% BSA) were diluted at 1:25, 1:50, 1:100, 1:200, and 1:400, respectively, and added to the corresponding wells, 100 μL / well. Each dilution was repeated in 3 replicates and incubated at 37°C for 30 minutes.

[0090] After washing 5 times (300 μL / well, 30 seconds each time), add 100 μL of HRP-labeled rabbit anti-pig IgG (purchased from Abcam, 1:10000 dilution) to each well and incubate at 37°C for 30 minutes. After washing 5 times, add 100 μL of TMB substrate solution (purchased from Beijing Solarbio Science & Technology Co., Ltd., single component) to each well and incubate at room temperature in the dark for 10 minutes. Stop the reaction by adding 50 μL of 2M H2SO4 to each well and immediately measure the OD450nm value using a microplate reader.

[0091] The optimization criteria were a positive serum OD450nm value close to 1.0 and a maximum P / N ratio (positive OD / negative OD). The results are shown in Table 3-1. When the antigen coating concentration was 2 μg / mL and the serum dilution was 1:100, the positive OD450nm value was 1.026, and the P / N ratio reached its maximum (12.4). Therefore, the optimal antigen coating concentration was determined to be 2 μg / mL, and the optimal serum dilution was determined to be 1:100.

[0092] Table 3-1 Optimization results of antigen coating concentration and serum dilution factor (P / N value) Note: The data in the table are the mean ± standard deviation of three repeated experiments.

[0093] 3.3 Optimization of working concentration of enzyme-labeled secondary antibody HRP-labeled rabbit anti-pig IgG was diluted to 1:5000, 1:10000, 1:20000, and 1:40000, and ELISA was performed at the optimal antigen coating concentration (2 μg / mL) and optimal serum dilution (1:100). The results showed that the P / N value was the highest at a dilution of 1:10000 (12.4), and the positive OD450nm value was close to 1.0 (1.026). Therefore, 1:10000 was selected as the working concentration of the enzyme-labeled secondary antibody.

[0094] 3.4 Determination of Critical Values Using optimized reaction conditions (antigen coating concentration 2 μg / mL, serum dilution 1:100, enzyme-labeled secondary antibody 1:10000), 120 healthy pig serum samples that were negative for APP antibodies were tested, and the OD450nm value was measured.

[0095] The test results were statistically analyzed using SPSS 26.0 software. The distribution of OD450nm values ​​from 120 negative serum samples is as follows: mean 0.086, standard deviation 0.019, 95% confidence interval 0.083–0.089, and median 0.085. The data were normally distributed according to the Shapiro-Wilk test (P>0.05). Following standard ELISA interpretation procedures, the mean ± 3 SD was used as the positive cutoff value.

[0096] The calculation yields: Average value + 3SD = 0.086 + 3 × 0.019 = 0.143. For ease of calculation and practical operation, the critical value is adjusted to 0.15. That is, a sample with an OD450nm ≥ 0.15 is considered positive, and a sample with an OD450nm < 0.15 is considered negative.

[0097] Table 3-2 Distribution statistics of OD450nm values ​​in negative serum

[0098] Example 4: Reagent Kit Performance Validation 4.1 Sensitivity Verification 4.1.1 Determination of detection limit APP standard positive serum was serially diluted 2-fold starting from 1:100 (1:100, 1:200, 1:400...1:12800) and detected using the optimized ELISA method of this invention, with three replicates for each dilution. Simultaneously, ELISA plates coated with ApxIA, ApxIA, or OmpD single proteins were used as controls to compare detection sensitivity.

[0099] The results are shown in Table 4-1. The highest detection dilution of the kit of the present invention is 1:3200 (OD450nm = 0.164 > 0.15), while the highest detection dilutions of the single antigen-coated kits are: ApxⅠA 1:800 (OD450nm = 0.158), ApxⅡA 1:800 (OD450nm = 0.162), and OmpD 1:400 (OD450nm = 0.171). The results indicate that the detection sensitivity of the kit of the present invention (1:3200) is significantly higher than that of any single antigen-coated kit (the highest being only 1:800), representing a 4-fold increase in sensitivity.

[0100] Table 4-1 Sensitivity test results (OD450nm value, Mean±SD)

[0101] 4.1.2 Sensitivity Statistical Analysis Independent samples t-tests were performed using SPSS 26.0 to compare the OD450nm values ​​of the kit of this invention with those of each single antigen kit at a 1:1600 dilution. The results showed that the OD450nm value of the kit of this invention (0.278±0.022) was significantly higher than that of ApxⅠA coated kit (0.158±0.014, P<0.01), ApxⅡA coated kit (0.172±0.016, P<0.01), and OmpD coated kit (0.098±0.009, P<0.001). This result indicates that the fusion protein coated plate has a significant synergistic enhancement effect, rather than a simple sum of the detection effects of the three antigens.

[0102] 4.2 Specificity Validation 4.2.1 Cross-reactivity detection The following reference sera were tested using the optimized ELISA method of this invention (three replicates for each serum). All reference sera were purchased from the China Institute of Veterinary Drug Control or prepared in-house and validated by other methods: Porcine reproductive and respiratory syndrome virus (PRRSV) positive serum; Classical swine fever virus (CSFV) positive serum; Porcine pseudorabies virus (PRV) positive serum; Porcine circovirus type 2 (PCV2) positive serum; Streptococcus suis (SS) positive serum; Haemophilus parasuis (HPS) positive serum; APP negative serum; APP positive serum (immunized pig source, titer >1:10). 5 ).

[0103] The results are shown in Table 4-2. Only the APP-positive serum test result was positive (OD450nm = 0.986±0.042 >0.15). The OD450nm values ​​of other pathogen-positive and negative sera were all less than 0.12, far below the critical value of 0.15, and were therefore judged as negative. One-way ANOVA showed that there was a highly significant difference between the APP-positive serum and the other groups (P<0.001). The results indicate that the kit of this invention has no cross-reactivity with the positive sera of these common pathogens and has good specificity.

[0104] Table 4-2 Specific Detection Results

[0105] 4.3 Repeatability Validation 4.3.1 Intra-batch reproducibility: Three ELISA plates prepared from the same batch (batch number 20250301) were used to test 10 positive sera and 10 negative sera, respectively. Each serum sample was tested in 4 replicate wells on the same plate. The mean and standard deviation of OD450nm for each serum sample were calculated, and then the intra-batch coefficient of variation (CV = SD / Mean × 100%) was calculated.

[0106] 4.3.2 Inter-batch reproducibility: Three different batches of ELISA plates (batch numbers 20250301, 20250302, and 20250303) were used to test the 20 serum samples mentioned above. Four replicate wells were set for each serum sample per batch, and the inter-batch coefficient of variation was calculated. The results are shown in Table 4-3. The intra-batch coefficient of variation for positive serum was 3.2%-6.8%, and for negative serum it was 4.1%-7.3%; the inter-batch coefficient of variation for positive serum was 5.6%-8.9%, and for negative serum it was 6.2%-9.4%. All coefficients of variation were less than 10%, indicating that this kit has good reproducibility.

[0107] Table 4-3 Repeatability test results

[0108] 4.4 Stability Verification 4.4.1 Thermal stability test: The same batch of reagent kits (batch number 20250301) were stored at 4℃ and 37℃ respectively, and taken out at different time points (0, 3, 5, 7, 10, 14 days) to test the same set of positive and negative sera (1 positive serum sample and 1 negative serum sample, 3 replicates each) to observe the stability of the reagent kit.

[0109] 4.4.2 Long-term storage test: The same batch of reagent kits was stored at 4°C and taken out at 0, 1, 3, 6, 9 and 12 months respectively to test the above positive and negative serum.

[0110] The results are shown in Table 4-4. After 12 months of storage at 4℃, the OD450nm value of positive serum decreased from the initial 1.026 to 0.938, a decrease of approximately 8.6%; the OD450nm value of negative serum increased from 0.083 to 0.091. After 7 days of storage at 37℃, the OD450nm value of positive serum decreased by approximately 12.3% (from 1.026 to 0.900); the OD450nm value of negative serum increased from 0.083 to 0.097. Based on the Arrhenius formula, the shelf life of the kit at 4℃ is estimated to be 12-18 months.

[0111] Table 4-4 Stability Test Results

[0112] 4.5 Compliance Rate Verification 4.5.1 Clinical sample testing: 200 clinical swine serum samples (collected from large-scale pig farms in Zhejiang, Jiangsu and Guangdong provinces, including immunized pigs, naturally infected pigs and healthy pigs) were tested in parallel using the kit of this invention and a certain imported commercial APP antibody detection kit (based on Apx IV antigen, IDEXX).

[0113] 4.5.2 Statistical Analysis Methods: Using the test results of imported reagent kits as a reference standard, the relative sensitivity, relative specificity, and overall concordance rate of the reagent kit of this invention were calculated. Simultaneously, the Kappa value was calculated to evaluate the consistency between the two methods (Kappa ≥ 0.75 indicates high consistency, 0.4 ≤ Kappa < 0.75 indicates moderate consistency, and Kappa < 0.4 indicates low consistency).

[0114] The results are shown in Tables 4-5. Of the 200 clinical samples, 189 samples showed consistent results between the two kits, with an overall concordance rate of 94.5%. Specifically, 120 samples tested positive with the imported kit, while 115 samples tested positive with the kit of this invention, resulting in a relative sensitivity of 95.8%. 80 samples tested negative with the imported kit, while 74 samples tested negative with the kit of this invention, resulting in a relative specificity of 92.5%. The Kappa value was 0.89 (95% confidence interval: 0.83–0.95), indicating a high degree of consistency between the two kits.

[0115] Table 4-5 Compliance Rate Verification Results

[0116] 4.5.3 Analysis of Inconsistent Samples Further analysis was conducted on 11 inconsistent samples (6 positive for this invention / negative for imported samples, and 5 negative for this invention / positive for imported samples): Of the 6 positive for this invention / negative for imported samples, 4 were positive for ApxIA, 1 for ApxIA, and 1 for OmpD, as verified by indirect ELISA (coated with ApxIA, ApxIA, and OmpD respectively). This indicates that these samples may contain antibodies against specific toxins produced after infection or immunization, but these antibodies cannot be detected by the imported kit based on the ApxIV antigen. Of the 5 negative for this invention / positive for imported samples, 3 were false positives from the imported kit (verified negative by Western blot), and 2 were false negatives from the kit of this invention (possibly due to low antibody titers, near the cutoff value).

[0117] The above results show that the kit of the present invention can detect some specific antibodies that cannot be detected by imported kits, and has a wider detection coverage.

[0118] Example 5: Establishment and Validation of the Blocking ELISA Method To meet different detection needs (such as the need for higher specificity, reduced sample pre-dilution steps, and reduced background interference), this invention can also establish a blocking ELISA method based on the monoclonal antibody prepared in Example 2. Blocking ELISA effectively reduces non-specific reactions and improves detection specificity by having the antibody in the serum of the test sample compete with the enzyme-labeled monoclonal antibody for binding to the solid-phase antigen.

[0119] 5.1 Preparation of enzyme-labeled monoclonal antibodies 5.1.1 Preparation before labeling: Take the monoclonal antibody 3A-F6 purified in Example 2 (2.35 mg / mL, PBS buffer), dialyze overnight at 4°C with 0.1 M carbonate buffer (pH 9.6), and adjust the antibody concentration to 2.0 mg / mL. Take 5 mg of HRP and dissolve it in 0.5 mL of deionized water for later use.

[0120] 5.1.2 Oxidation of sodium periodate: Slowly add 0.2 mL of freshly prepared 0.1 M NaIO4 solution to the HRP solution, mix well, and react at 4 °C in the dark for 20 minutes. After the reaction is complete, add 0.2 mL of 0.1 M ethylene glycol and continue the reaction in the dark for 10 minutes to terminate the oxidation reaction.

[0121] 5.1.3 Antibody conjugation: Add the oxidized HRP solution dropwise to the antibody solution while gently stirring. Adjust the total volume to 2.5 mL with 0.1 M carbonate buffer (pH 9.6). Incubate overnight (approximately 16 hours) at 4°C in the dark.

[0122] 5.1.4 Reduction and Purification: Add 0.1 mL of freshly prepared 5 mg / mL NaBH4 solution to the reaction solution and react at 4°C in the dark for 2 hours. After the reaction, dialyze against PBS (pH 7.4) overnight at 4°C to remove free HRP and unreacted reagents. Further purify the dialyzed labeled antibody using a Sephadex G-200 column, elute with PBS (pH 7.4), collect the protein peaks, and measure the OD of each tube. 280 nm and OD 403 nm, calculate the RZ value (Reinheitzahl = OD) 403 / OD 280 Collect fractions with an RZ value > 0.6 (the RZ value of successfully labeled HRP-antibody complexes is usually between 0.5 and 0.8), combine them, add 0.02% ProClin 300 as a preservative, aliquot and store at -20°C protected from light for later use.

[0123] 5.1.5 Determination of Labeled Antibody Titer: The titer of HRP-labeled antibodies was determined using an indirect ELISA method. The fusion protein (2 μg / mL) was coated onto an ELISA plate. HRP-labeled antibodies were serially diluted starting at 1:500 (1:500, 1:1000, 1:2000…1:64,000), and the OD450nm value was measured using standard ELISA procedures. The highest dilution with OD450nm ≥ 1.0 was taken as the labeled antibody titer. The results (Table 5-1) showed that the OD450nm value of the HRP-labeled antibody was 1.128 at a 1:8000 dilution, decreasing to 0.682 at a 1:16,000 dilution. The titer of the labeled antibody was determined to be 1:8000 (i.e., working concentration 1:4000–1:8000). The antibody maintained high immunoreactivity after labeling, indicating successful labeling.

[0124] Table 5-1 Results of HRP-labeled antibody titer determination

[0125] 5.2 Optimization of blocking ELISA reaction conditions 5.2.1 Optimization of antigen coating concentration: The fusion protein was coated onto ELISA plates at concentrations of 1, 2, 4, and 8 μg / mL and incubated overnight at 4°C. Using a fixed dilution of the enzyme-labeled monoclonal antibody (1:4000), positive and negative sera (3 samples each) were tested, with the highest P / N value used as the optimization criterion. The results (Table 5-2) showed that the highest P / N value (8.2) was achieved at an antigen coating concentration of 2 μg / mL, similar to 4 μg / mL but with a lower background. Therefore, 2 μg / mL was selected as the optimal coating concentration.

[0126] Table 5-2 Results of Antigen Coating Concentration Optimization

[0127] 5.2.2 Optimization of the working concentration of enzyme-labeled monoclonal antibody: Under the optimal antigen coating concentration (2 μg / mL), HRP-labeled antibody was diluted to 1:2000, 1:4000, 1:8000, and 1:16000, and positive and negative sera (3 samples each) were tested. The optimization criteria were high blocking rate and low OD450nm value of negative serum (the blocking rate calculation formula is shown in 5.3.2). The results showed (Table 5-3) that when the enzyme-labeled monoclonal antibody was diluted to 1:4000, the blocking rate of positive serum reached 78.6%, while the blocking rate of negative serum was only 6.8%, showing the most significant difference. Therefore, 1:4000 was selected as the optimal working concentration of the enzyme-labeled monoclonal antibody.

[0128] Table 5-3 Results of Optimization of Working Concentration of Enzyme-Labeled Monoclonal Antibody

[0129] 5.2.3 Optimization of Competitive Reaction Time: Under optimal reaction conditions, the effects of competitive reaction times (15 minutes, 30 minutes, 45 minutes, and 60 minutes) on the detection results were compared. The results showed (Table 5-4) that the positive serum blocking rate reached 76.8% at 30 minutes, and further extending the reaction time did not significantly increase the blocking rate, while the negative serum blocking rate increased slightly. Therefore, 30 minutes was selected as the optimal competitive reaction time.

[0130] Table 5-4 Results of Competition Response Time Optimization

[0131] 5.3 Procedures and Judgment Criteria for Blocking ELISA 5.3.1 Operating Procedures Based on the above optimization results, the optimal procedure for blocking ELISA is determined as follows: (1) Coating: The fusion protein purified in Example 1 was diluted to 2 μg / mL with coating buffer (0.05M carbonate buffer, pH 9.6), added to a 96-well microplate, 100 μL / well, and coated overnight at 4°C (12-14 hours).

[0132] (2) Washing and blocking: Discard the coating solution, wash 3 times with PBST (PBS containing 0.05% Tween-20), 300 μL / well, let stand for 30 seconds each time, and pat dry. Add 200 μL of blocking solution (PBST containing 2% BSA) to each well and block at 37°C for 2 hours. Discard the blocking solution and pat dry.

[0133] (3) Competitive reaction: Dilute the serum to be tested with sample diluent (PBST containing 0.5% BSA) at a ratio of 1:10, mix with an equal volume of HRP-labeled monoclonal antibody (3A-F6-HRP, diluted 1:4000), and pre-incubate at 37°C for 30 minutes. Add 100 μL of the mixture to each well and incubate at 37°C for 30 minutes.

[0134] (4) Washing: Discard the liquid in the well, wash 5 times with PBST, 300 μL / well, let stand for 30 seconds each time, and pat dry.

[0135] (5) Color development: Add 100 μL of TMB substrate solution to each well and develop color at room temperature in the dark for 10 minutes.

[0136] (6) Termination and reading: Add 50 μL of 2M H2SO4 to each well to terminate the reaction, and immediately measure the OD450nm value with an enzyme-linked immunosorbent assay (ELISA) reader.

[0137] 5.3.2 Calculation of blocking rate. The formula for calculating the blocking rate is as follows: Blocking rate (%) = (1 - OD450nm of sample well / OD450nm of negative control well) * 100%.

[0138] The negative control wells consisted of a mixture of SPF porcine negative serum (1:10 dilution) and enzyme-labeled monoclonal antibody.

[0139] 5.3.3 Determination of the cutoff value: Under optimized reaction conditions, 120 serum samples from healthy pigs raised in SPF-grade conditions and negative for APP antibodies were tested, and the blocking rate was calculated. Statistical analysis showed that the mean blocking rate of the 120 negative serum samples was 8.6%, and the standard deviation was 4.2%. The cutoff value was calculated using the mean + 3SD: Cutoff value = 8.6% + 3 × 4.2% = 21.2%. For ease of calculation and practical operation, the cutoff value was adjusted to 20%. That is, a sample with a blocking rate ≥ 20% is considered positive, and a sample with a blocking rate < 20% is considered negative.

[0140] Table 5-5 Distribution of blocking rates of negative serum (n=120)

[0141] 5.4 Performance Validation of the Blocking ELISA Method 5.4.1 Sensitivity Validation: APP standard positive serum was serially diluted from 1:10 (1:10, 1:20, 1:40…1:1280) and detected using the blocking ELISA method, with three replicates for each dilution. An indirect ELISA method (established in Example 3) was used as a control. The results are shown in Tables 5-6. The highest detection dilution for the blocking ELISA method was 1:320 (blocking rate = 21.3% > 20%), while the highest detection dilution for the indirect ELISA method was 1:3200. The blocking ELISA method has approximately 10 times lower sensitivity than the indirect ELISA method, but higher specificity, making it suitable for detection scenarios requiring higher specificity (such as distinguishing between vaccine immunization and natural infection).

[0142] Table 5-6 Comparison of sensitivity between blocking ELISA and indirect ELISA

[0143] 5.4.2 Specificity Validation: Positive sera for pathogens such as PRRSV, CSFV, PRV, PCV2, SS, and HPS were detected using a blocking ELISA method (same as in Example 4.2), with three replicates for each sample. The results are shown in Tables 5-7. Only APP-positive sera showed a positive result (blocking rate = 76.8%), while the blocking rates for other pathogen-positive and negative sera were all less than 15%, far below the critical value of 20%. The results indicate that the blocking ELISA method has no cross-reactivity with positive sera of these common pathogens and exhibits good specificity.

[0144] Table 5-7 Results of Specific Detection of Blocking ELISA

[0145] 5.4.3 Reproducibility Validation: Three ELISA plates prepared from the same batch were used to test 10 positive serum samples and 10 negative serum samples, with four replicate wells for each serum sample. The intra-batch coefficient of variation (COP) was calculated. Three ELISA plates from different batches were used to test the aforementioned 20 serum samples, and the inter-batch COP was calculated. The results are shown in Table 5-8. The intra-batch COP for positive serum was 4.2%-7.8%, and for negative serum it was 5.3%-8.6%; the inter-batch COP for positive serum was 6.5%-9.8%, and for negative serum it was 7.2%-10.5%. All COPs were <11%, indicating that the blocking ELISA method has good reproducibility.

[0146] Table 5-8 Results of Repeatable ELISA Testing

[0147] 5.4.4 Concordance Validation with Indirect ELISA: 150 clinical swine serum samples (including immunized pigs, naturally infected pigs, and healthy pigs) were tested in parallel using both the blocking ELISA method and the indirect ELISA method (established in Example 3), and the concordance rates of the two methods were compared. The results are shown in Tables 5-9. A total of 136 samples showed consistent results between the two methods, with an overall concordance rate of 90.7%. Specifically, 85 samples were positive by indirect ELISA, and 79 were positive by blocking ELISA, resulting in a concordance rate of 92.9%; 65 samples were negative by indirect ELISA, and 57 were negative by blocking ELISA, resulting in a concordance rate of 87.7%. The Kappa value was 0.81, indicating a high degree of consistency between the two methods. Inconsistent samples mainly appeared in samples with low antibody titers (close to the cutoff value). Blocking ELISA, due to its higher specificity, had a lower false positive rate.

[0148] Table 5-9 Validation results of concordance rate between blocking ELISA and indirect ELISA

[0149] 5.5 Comparison of application scenarios between blocking ELISA and indirect ELISA Based on the above verification results, the blocking ELISA and indirect ELISA methods established in this invention each have their advantages and can be selected for different application scenarios:

[0150] The present invention will be further illustrated below with reference to specific embodiments, but these embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in this technical field. Unless otherwise specified, the reagents and materials used in the following embodiments are commercially available.

[0151] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A fusion protein, characterized in that, The fusion protein comprises ApxⅠA protein, ApxⅡA protein, and OmpD protein of Actinobacillus pleuropneumoniae, and the three proteins are linked by a flexible peptide linker; the amino acid sequence of the fusion protein is shown in SEQ ID NO.

4.

2. A nucleic acid molecule encoding the fusion protein of claim 1, wherein The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.

5.

3. A monoclonal antibody, characterized in that, The monoclonal antibody can specifically bind to the fusion protein of claim 1; wherein the nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO. 6, and the nucleotide sequence encoding the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.

7.

4. A porcine contagious pleuropneumonia antibody detection kit, characterized by, The kit includes a solid-phase carrier coated with the fusion protein of claim 1.

5. The kit of claim 4, wherein The kit also includes HRP-labeled rabbit anti-pig IgG, sample diluent, concentrated wash solution, substrate solution, stop solution, positive control, and negative control.

6. The kit of claim 4, wherein The coating concentration of the fusion protein is 2 μg / mL.

7. A porcine contagious pleuropneumonia antibody blocking ELISA test kit characterized in that, The kit comprises a solid-phase carrier coated with the fusion protein of claim 1, and the monoclonal antibody of claim 3.

8. The kit of claim 7, wherein The monoclonal antibody is an HRP-labeled monoclonal antibody with a working concentration of 1:4000.

9. The use of the fusion protein according to claim 1 in the preparation of a porcine infectious pleuropneumonia antibody detection product.

10. The use of the monoclonal antibody according to claim 3 in the preparation of a porcine infectious pleuropneumonia antibody detection product.